Alternatives to Mochi Health

The brand-access marketplace: real FDA-approved pens and oral options with insurance-style navigation — but a required video visit, a 28-day billing cycle, and prices that sit well above the compounded field.

The sum is transparent and it is the seller's own: $99 a month for the service, plus the manufacturer's charge — $299 for the Zepbound starter pen, $149 for the Wegovy pill — giving $398 and $248. The first month is $25 instead of $99. Both of those manufacturer figures are LillyDirect's and NovoCare's own, so the arithmetic can be checked from outside, and it holds. What is not published is the ladder as your dose climbs.

A sublingual (under-the-tongue), not injectable, GLP-1 program — $189/mo semaglutide and $319/mo tirzepatide on a 6-month prepay plan, $209/mo and $359/mo on a shorter 2-month plan — serving 34 states plus DC.

AskRx solves the pricing question most of this page leaves open, and creates a different one. Its care fee is itemized in its own footnote — $90/month physician visit, $10/month fulfilment, $100 total — and the medication is billed separately through its own pharmacy, at cost, with both halves shown at checkout. If you have ever wondered how much of a blended monthly price is the drug and how much is margin, this is the provider that answers it. It is FDA-approved only ('No compounded meds'), so the options are the Wegovy pen, the Wegovy pill, Zepbound in pen or KwikPen form, and Foundayo, the oral tirzepatide. All 50 states, board-certified physicians with obesity-medicine training, unlimited messaging, monthly titration, cancel anytime. Two logistics notes that matter on a workday. First, $100 is a floor: no medication price is published, so your real monthly total is unknown until checkout and depends on coverage. Second — and read this one if scheduling is your constraint — 'video visits available in select states' means the async route is not universal here, so confirm your own state before assuming you can do this without a call.

A cardiometabolic telehealth platform built around diabetes care that also treats obesity — $149/mo self-pay or free with insurance, one price covering brand GLP-1s, labs, devices and a real multi-disciplinary care team, though it publishes no state list at all.

An established longevity-telehealth brand with a microdose-first GLP-1 menu — starting at $99/mo microdosing semaglutide, $159/mo microdosing tirzepatide — plus brand-name Wegovy/Zepbound access-and-monitoring for a separate $50–$65 fee (drug cost billed apart).

GoodRx now runs a real prescriber, not just a coupon, and the two should not be confused. GoodRx Care Direct charges $39 a month for unlimited online care and bills the medication separately — read live on 2026-08-26, it lists the Wegovy pill as low as $149 a month, the Wegovy and Wegovy HD pens as low as $199 and the Zepbound KwikPen as low as $299, all under the label only FDA-approved medications, with no compounded tier at all. Every one of those is an as low as rather than a rate, so treat them as the bottom of a dose ladder. One thing here is better than almost anything else on this list for a working parent: GoodRx says a visit with a healthcare professional takes place via text, call or video, which means a text-only path exists. One thing is worse, and it belongs in the open. In February 2023 the Department of Justice, acting for the Federal Trade Commission, filed a complaint and a stipulated order in the Northern District of California, and GoodRx Holdings, Inc. agreed to a $1.5 million civil penalty over allegations that it shared users' prescription and health information with advertising platforms contrary to its own privacy promises; the order permanently bars it from disclosing user health information for advertising, and the case caption names GoodRx Care, the service reviewed here. That is a data question rather than a medicine question, and it is exactly the kind of thing worth knowing before you type your health history into a form.

The manufacturer's own channel for brand Wegovy — $149/mo self-pay or as low as $25/mo with commercial insurance — but it requires your own existing prescription and offers no tirzepatide, since that's a different company's drug.

Names four specific 503A compounding pharmacy partners directly — from $150/mo semaglutide, $241/mo tirzepatide on a 6-month plan, available as injection, drops, or pills — though state coverage isn't published.